BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, today announced the successful acquisition of BioDuro’s drug product development and manufacturing operations in Irvine, California, resulting in the formation of Forma Life Sciences, Inc. (FORMA), a Delaware corporation established to hold and operate the acquired assets.

The transaction includes two highly accredited facilities supporting U.S.-based development and manufacturing of high-quality pharmaceutical drug products. Now operating under the FORMA name, the Irvine Fairbanks facility comprises approximately 65,000 sq. ft. and has produced high-value pharmaceutical drug products for more than 20 years, with a strong regulatory track record including multiple FDA inspections with favorable outcomes. In parallel, the Irvine Jeronimo facility encompasses approximately 40,000 sq. ft. and is focused on development and scale-up manufacturing of clinical-phase drug products, with purpose-built manufacturing suites designed to enable advanced oral solid dosage technologies.

“This acquisition represents a meaningful expansion of our capabilities and reinforces our long-standing commitment to U.S.-based development, manufacturing, and supply of critical drug products for both domestic and global partners,” said Cyrus K. Mirsaidi, Chairman of BioSelective Capital Investments. “We sincerely appreciate the collaborative engagement with BioDuro and its investors throughout this transaction and look forward to continuing the relationship as a trusted U.S. manufacturing partner for oral dosage forms.”

Following the acquisition, Cyrus K. Mirsaidi will serve as Executive Chairman and Acting Chief Executive Officer of FORMA. The company is focused on ensuring continuity for existing clients while laying the foundation for the next phase of growth in its core commercial drug product manufacturing business. FORMA also plans to expand into differentiated capabilities in bioavailability enhancement, including advancements in amorphous solid dispersion technologies and rapid formulation prototyping enabled by iterative in silico modeling.

About BioSelective Capital Investments

BioSelective Capital Investments, and Shayan Enterprises, LLC, a Utah-based risk-capital investment company, selectively invest in the biopharmaceutical sector through collaborations that tightly merge equity investments with hands-on operational partnerships. With over 10 active projects our investments have a track record for delivering sustainable revenue growth and maximized profit margins with careful attention to sales growth and cost containment, especially for young start-ups and pre-profit companies. We deploy motivated and culturally diverse teams, along with capital, for well-defined and measurable goals to build operational accountability and to energize sales teams to meet critical milestones and revenue targets. We are BioSelective.

For more information, please visit http://www.bioselective.com/

About BioDuro

BioDuro, an Advent portfolio company, is a CRDMO with a 30-year proven track record. Headquartered in Irvine, California, BioDuro employs more than 2,000 scientists with deep expertise in small- and large-molecule discovery, development, and manufacturing. We provide fully integrated drug discovery services spanning chemistry, biology, and pharmacokinetics (DMPK), along with comprehensive IND-enabling capabilities, including both drug substance and drug product development.

For more information, please visit http://www.bioduro.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20260120433880/en/

This acquisition represents our commitment to U.S.-based development, manufacturing, and supply of critical drug products for both domestic and global partners